ERBB2 and breast carcinoma: Given the differential data regarding the benefit of anthracyclines in both HER2− and HER2+ breast cancer as well as the clear preclinical data showing that transfection of the HER2 gene itself does not impart sensitivity to anthracyclines, the search for predictive biomarkers continues.